PHAT Key Statistics, Chart & Performance
The current stock price of PHAT is 15.015 USD. In the past month the price increased by 3.2%. In the past year, price increased by 116.35%.
PHAT Latest News, Press Relases and Analysis
PHAT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 48.37 | 1.01T | ||
| JNJ | JOHNSON & JOHNSON | 19.69 | 492.44B | ||
| MRK | MERCK & CO. INC. | 12.55 | 274.34B | ||
| PFE | PFIZER INC | 7.96 | 144.87B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 8.52 | 113.72B | ||
| ZTS | ZOETIS INC | 20.06 | 56.04B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.77 | 23.19B | ||
| VTRS | VIATRIS INC | 5.48 | 14.70B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 24.45 | 11.66B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 8.54B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 5.53B | ||
| CRNX | CRINETICS PHARMACEUTICALS IN | N/A | 5.05B |
Related stock screener links
About PHAT
Company Profile
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 427 full-time employees. The company went IPO on 2019-10-25. The firm is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
Company Info
PHATHOM PHARMACEUTICALS INC
100 Campus Drive, Suite 102
Florham Park NEW JERSEY 07932 US
CEO: Terrie Curran
Employees: 427
Phone: 18777428466
PHATHOM PHARMACEUTICALS INC / PHAT FAQ
What does PHAT do?
Phathom Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel treatments for gastrointestinal diseases. The company is headquartered in Florham Park, New Jersey and currently employs 427 full-time employees. The company went IPO on 2019-10-25. The firm is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s product candidates include VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker, or potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.
What is the stock price of PHATHOM PHARMACEUTICALS INC today?
The current stock price of PHAT is 15.015 USD. The price decreased by -3.75% in the last trading session.
Does PHATHOM PHARMACEUTICALS INC pay dividends?
PHAT does not pay a dividend.
How is the ChartMill rating for PHATHOM PHARMACEUTICALS INC?
PHAT has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
How is the valuation of PHATHOM PHARMACEUTICALS INC (PHAT) based on its PE ratio?
PHATHOM PHARMACEUTICALS INC (PHAT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-3.82).
Can you provide the market cap for PHATHOM PHARMACEUTICALS INC?
PHATHOM PHARMACEUTICALS INC (PHAT) has a market capitalization of 1.07B USD. This makes PHAT a Small Cap stock.
Can you provide the upcoming earnings date for PHATHOM PHARMACEUTICALS INC?
PHATHOM PHARMACEUTICALS INC (PHAT) will report earnings on 2026-03-04, after the market close.
PHAT Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to PHAT. When comparing the yearly performance of all stocks, PHAT is one of the better performing stocks in the market, outperforming 95.05% of all stocks.
PHAT Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to PHAT. Both the profitability and financial health of PHAT have multiple concerns.
PHAT Financial Highlights
Over the last trailing twelve months PHAT reported a non-GAAP Earnings per Share(EPS) of -3.82. The EPS increased by 32.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -114.26% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
PHAT Forecast & Estimates
16 analysts have analysed PHAT and the average price target is 22.85 USD. This implies a price increase of 52.17% is expected in the next year compared to the current price of 15.015.
For the next year, analysts expect an EPS growth of 39.18% and a revenue growth 243.62% for PHAT